XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Interest in joint venture (Tables)
9 Months Ended
Sep. 30, 2022
Interests In Other Entities [Abstract]  
Schedule of movement in interest in joint venture The table below provides a rollforward of the Company’s interest in Overland ADCT BioPharma as of September 30, 2022 and 2021, respectively.
(in KUSD)
Interest in joint venture
January 1, 202241,236 
Share of results in joint venture(6,549)
September 30, 202234,687 
January 1, 202147,908 
Share of results in joint venture(3,906)
September 30, 202144,002 
Summary of financial information in join venture
The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company’s share of those amounts.
(in KUSD)As of
Summarized Balance SheetSeptember 30, 2022December 31, 2021
Cash and cash equivalents24,445 39,318 
Prepaid and other current assets516 15 
Intangible assets48,040 48,040 
Total liabilities3,711 2,828 
Net assets69,290 84,545 
Summarized Statement of Comprehensive LossThree months ended September 30,Nine months ended September 30,
2022202120222021
Operating expenses4,950 4,465 14,317 8,120 
Net loss4,346 4,511 13,009 7,972